๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease?

โœ Scribed by Rinat Tabakman; Shimon Lecht; Philip Lazarovici

Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
172 KB
Volume
26
Category
Article
ISSN
0265-9247

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

A rationale for monoamine oxidase inhibi
A rationale for monoamine oxidase inhibition as neuroprotective therapy for parkinson's disease
โœ Prof. C. W. Olanow ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 719 KB

Neurons in the substantia nigra may be vulnerable to oxidant stress because (a) the metabolism of dopamine generates peroxides. which, in the presence of iron. can lead to the formation of the highly reactive hydroxyl free radical; and (b) neuromelanin within nigral neurons can bind metals such as i

Association of a monoamine oxidase B all
Association of a monoamine oxidase B allele with Parkinson's disease
โœ Janice H. Kurth; Dr. Matthias C. Kurth; Shirley E. Poduslo; John D. Schwankhaus ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 685 KB

Monoamine oxidase B (MAO-B) is implicated in the cause of Parkinson's disease (PD) because of its role in metabolizing the neurotoxin l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine, and forming H,02 during dopamine metabolism. Altered MAO-B activity has been observed in PD platelets. Polymerase chain

Hereditary variations in monoamine oxida
Hereditary variations in monoamine oxidase as a risk factor for Parkinson's disease
โœ Gokhan S. Hotamisligil; A. Sule Girmen; J. Stephen Fink; Elizabeth Tivol; Christ ๐Ÿ“‚ Article ๐Ÿ“… 1994 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 655 KB

## Abstract Parkinson's disease (PD) is a common neurodegenerative disorder caused by loss of dopaminergic neurons in the brainstem. Recent studies suggest that several genes may have a role in determining individual susceptibility to this disease, and the degradative enzyme monoamine oxidase (MAO)

Neuroprotective therapy in Parkinson's d
Neuroprotective therapy in Parkinson's disease and motor complications: A search for a pathogenesis-targeted, disease-modifying strategy
โœ C. Warren Olanow; Joseph Jankovic ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 78 KB ๐Ÿ‘ 1 views

The introduction of levodopa in the late 1960s represented a landmark in the therapy of Parkinson's disease (PD). However, motor complications of chronic levodopa therapy have emerged as a major limitation of this otherwise effective therapy. Advancing medical and surgical treatment of these complic

Monoamine oxidase B polymorphism, cigare
Monoamine oxidase B polymorphism, cigarette smoking and risk of Parkinson's disease: A study in an Asian population
โœ Tan, E.K. ;Chai, A. ;Lum, S.Y. ;Shen, H. ;Tan, C. ;Teoh, M.L. ;Yih, Y. ;Wong, M. ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 59 KB ๐Ÿ‘ 3 views

## Abstract Cigarette smoking is associated with reduced monoamine oxidase B (MAO B) activity. Polymorphisms of the __MAO B__ gene may modify the relationship between smoking and Parkinson's Disease (PD). We examined the association of MAO B intron 13 G/A polymorphism and risk of PD, and the modula